Biopharma A Cautiously Optimistic Outlook for 2025
A Cautiously Optimistic Outlook for Biopharma in 2025 The biopharma sector is poised for a cautious but optimistic rebound in 2025, driven by renewed investment, the growing influence of artificial…
Read MoreBiopharma A Cautiously Optimistic Outlook for 2025
Alzheimer’s Disease Breakthrough Unveiling the Mechanism Behind Lecanemab’s Role in Slowing Progression 2025
New Insights into Lecanemab’s Role in Slowing Alzheimer’s Disease Progression A groundbreaking study led by Professor Kenjiro Ono of the Institute of Medical, Pharmaceutical, and Health Sciences at Kanazawa University,…
Osteosarcoma Breakthrough GSK’s B7-H3 ADC GSK’227 Gains FDA Breakthrough Designation
GSK Receives FDA Breakthrough Therapy Designation for GSK5764227 in Osteosarcoma Treatment GSK plc (LSE/NYSE: GSK) announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for…
Allergan Aesthetics Launches 3rd Annual CoolMonth: Exclusive Deals on CoolSculpting\u00ae Elite
CoolMonth Returns with Exciting Offers on CoolSculpting® Elite by Allergan Aesthetics Allergan Aesthetics, an AbbVie company has announced the return of its third annual CoolMonth celebration, showcasing CoolSculpting® Elite. This…
CVS Health and Aetna Allocate Award $750,000 to Support Health Initiatives in Illinois
CVS Health and Aetna Allocate $750,000 in Grants to Advance Health Outcomes Across Illinois CVS Health and Aetna Better Health® of Illinois, a CVS Health company, recently announced a combined…
HUB Organoids Acquired by Merck to Expand Biology Portfolioby By $500 Million
HUB Organoids Merck Completes Acquisition of HUB Organoids Holding B.V., Expanding Next-Generation Biology Portfolio Merck, a global leader in science and technology, has finalized its acquisition of HUB Organoids Holding…
Trispecific Breakthrough WuXi Biologics Partners with Candid Therapeutics on T-Cell Engager Agreement 2024
Trispecific WuXi Biologics a globally recognized Contract Research, Development, and Manufacturing Organization (CRDMO), has announced a groundbreaking partnership with Candid Therapeutics, Inc. (“Candid”). Candid is a clinical-stage biotechnology firm aiming…
HIV Testing WHO Unveils Positive New Guidelines for Lenacapavir and Updated Recommendations 2025
HIV Testing WHO Launches Guideline Development Group to Establish New HIV Prevention and Testing Standards for Lenacapavir The World Health Organization (WHO) has announced the formation of a new Guideline…
Biopharma Leaders Head to JPMorgan in Search of a Game-Changing M&A Boost to Revive Market Sentiment 2025
Biopharma Leaders M&A Didn’t Deliver as Expected in 2024: Biopharma Turns to JPMorgan Healthcare Conference for Optimism Biopharma Leaders the much-anticipated mergers and acquisitions (M&A) wave that the biopharma industry…
Gastric Cancer NMPA Approves VYLOYTM for Breakthrough Advanced Gastric Cancer Treatment 2025
Astellas Pharma recently announced the approval Gastric Cancer of VYLOYTM (zolbetuximab) by China’s National Medical Products Administration (NMPA) for first-line treatment of locally advanced unresectable or metastatic human epidermal growth…
Revolution Medicines Triumphantly Closes $862.5M Upsized Offering and Underwriters Option
Revolution Medicines, a clinical-stage oncology company focused on developing targeted therapies for patients with RAS-addicted cancers, recently announced the successful closing of its upsized underwritten public offering. The offering comprised…
Heart Disease Pearland Event Highlights Risks and Offers Valuable Free Heart and Kidney Health Screenings
Heart Disease: The Importance of Regular Health Screenings Care Access, a leading health Heart Disease and research company, is bringing its Heart & Kidney Health Screening initiative to Pearland, Texas.…